Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as the source for detailed financial results
Item EX-99.1 · Exhibit EX-99.1
- OPERA-01 Phase 3 enrollment complete; top-line data expected Q1 2027, creating a major near-term clinical catalyst for palazestrant
- Cash, equivalents, and marketable securities $461.1M, down from $505.4M at December 31, 2025
- Q2 net loss widened to $63.2M from $43.8M, reflecting heavier late-stage palazestrant and OP-3136 development spending
- GAAP R&D expense rose to $57.8M from $43.9M; G&A increased to $9.4M from $4.0M
- Bayer collaboration expands OP-3136 into prostate cancer; Phase 1b/2 enrollment planned for Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.